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ABSTRACT 
 
Identifying the genetic risk factors underlying a given disease is an essential step 
for informing effective drug targets, understanding disease architecture, and 
predicting at-risk individuals. A commonly applied approach for identifying novel 
disease-associated genes is the Genome Wide Association Study (GWAS) 
approach, in which a high number of individuals are sequenced and genetic 
variants are then tested for an association with disease status.  While the GWAS 
approach has identified countless disease-associated genes, there remain plenty 
of diseases for which our genetic understanding is still incomplete. One strategy 
for augmenting the GWAS approach is to incorporate additional omics data in 
order to prioritize biologically plausible candidate genes. 
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In this thesis work, we integrate network-based strategies with existing genetic 
analysis pipelines in order to identify novel Alzheimer’s disease (AD) genes. Two 
types of biological data inform the underlying structure of the networks: a) 
protein-protein interactions and b) gene expression in the human brain. Genes 
which interact or are co-expressed across similar conditions have been shown to 
have a higher probability of being functionally related. Using a set or previously 
known AD genes, we apply a network propagation strategy to score genes based 
upon their proximity to the known AD genes within these networks. Then we 
integrate the network score of each gene with its risk score from GWAS to 
identify novel candidates. To further affirm the reproducibility of findings, we 
further incorporate additional information in the form of knockout models in flies, 
bootstrap aggregation, and external genetic datasets. In addition to predicting 
novel genes, we are able to utilize regional co-expression networks to further 
understand how the known AD genes behave within the various sub-divisions of 
the brain. We find that regions of the brain which are known to have the earliest 
vulnerability to AD-induced neurodegeneration also tend to be where AD genes 
are highly correlated.  
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Chapter 1: Introduction and Rationale 
Genetic studies have achieved a strong understanding of the underlying roots of 
Mendelian diseases such as Huntington’s, Tay-Sachs, sickle cell, and several 
others [1-3]. However, diseases following a multigenic pattern of inheritance have 
required a vast number of studies to achieve even a partial understanding of the 
genetic roots of the diseases [4, 5]. For example, mutations in approximately 60 
genes have been reliably identified as contributing to genetic risk for Alzheimer’s 
disease (AD) (See Table 2.1). Despite the high volume of known AD-associated 
genes, estimates of the missing heritability of AD and other complex diseases 
are sizeable [4, 6]. Datasets with higher sample sizes and greater statistical 
power may eventually contribute to identifying remaining unknown AD-associated 
genes, but alternatively other forms of readily available omics data can also 
contribute to addressing this issue [4]. 
A challenge to incorporating multiple forms of biological data into combined 
analyses is identifying a framework that can suitably model all the various 
relationships and information contained in each type of data. One flexible 
framework is a graph, otherwise known as a network, which is a well-studied 
concept in computer science for representing similarities between entities and 
numerous other relationships [7-11]. In a graph, each entity is represented by a 
node and then nodes are connected by edges if a relationship between the two 
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nodes exists. Weights representing the strengths of these relationships can be 
appended to edges, and labels can be attached to nodes, allowing for a wide 
variety of algorithms to be applied. Graphs have been used to optimize 
commonly used resources such as internet search engines, social networks, 
economic models, public transportation routes, and many others [12, 13]. In the 
context of the systems biology research, network approaches have been applied 
to a wide variety of biological concepts such as predicting gene function, 
characterizing bacterial communities, generating novel drug targets, and 
identifying gene clusters associated with diseases [14-18]. The data underlying 
the networks in these approaches is commonly predicated on either protein-
protein interaction (PPI) or gene expression levels in specific biological 
conditions. Proteins which interact have a higher probability of having common 
pathways, a property referred to as functional linkage. Likewise, genes which are 
co-expressed in particular conditions are more likely to be co-regulated or share 
a functional role in those environments. These two concepts serve as the basis 
for the approaches described in this work. 
Many studies have applied network methodology to accommodate multi-omic 
analysis with success across a wide variety of diseases and phenotypes [19-25]. 
Gene expression has been integrated with a PPI network to identify new type 2 
diabetes genes [26]. Gene sets and label propagation in a PPI network have 
been used to determine similarities between neurodegenerative diseases [27]. 
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The work in the following chapters outlines another form of multi-omic integration 
that integrates previously known disease-related genes and Genome Wide 
Association Studies (GWAS) with network-based propagation in order to further 
characterize Alzheimer’s disease. As a result of this work, we identified several 
novel candidate AD genes and provide novel insights into how the expression of 
AD genes may contribute to the regional patterning of AD-based pathology in the 
brain. 
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Chapter 2: Integration of Network-Based Diffusion and Studies of Genetic 
Interaction Leads to Consistent Biological Insights of Alzheimer’s Disease 
and Novel AD Candidate Genes  
The discovery of disease-associated genomic variation has numerous clinical 
and scientific applications, including earlier disease prognosis, improved 
understanding of disease pathophysiology, and development of personalized 
treatment therapies [28]. A commonly used technique for identifying these 
mutations is the genome wide association study (GWAS) approach [29]. 
Typically, a large sample of affected and unaffected individuals are genotyped for 
many single nucleotide polymorphisms (SNPs) using a high-density microarray 
chip and then test statistically if the allele frequency of each variant is associated 
with disease status [29]. Significant associations in this first step (“discovery 
phase”) are deemed to be robust if they replicate in an independent cohort 
(“replication phase”). In this study, we focused on improving the replicability of 
GWAS results for Alzheimer disease (AD), although our methodology is 
applicable to genetic data for other diseases and traits. AD is a 
neurodegenerative disease resulting in irreversible dementia and memory loss 
with elevated prevalence in older populations [30]. Recent estimates suggest that 
approximately 5.4 million Americans have AD, and the number of cases of AD is 
expected to increase dramatically in future years if medical advances continue to 
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improve life expectancy, thereby allowing more individuals to reach ages where 
AD is on the rise [30]. 
Genetic studies of AD have led to identifying numerous AD associated genes 
such as APP [31], PSEN1 [32], and PSEN2 [33] for early onset AD (EOAD), as 
well as APOE [34, 35] and SORL1 [35, 36] for late onset AD (LOAD). Common 
variants in more than 20 other genes have been robustly associated with AD risk 
[35]. However, not all AD associated genes will reach genome wide significance 
in current datasets of sample sizes below 100,000 individuals. It is well 
recognized that incorporating other forms of biological data improves confidence 
in genetic findings [37-39]. 
Our computational framework is based on the following biological hypothesis.  If 
a known AD variant is associated with a gene that is involved in a particular 
biological process (BP) (e.g. inflammation), we assume as a probabilistic prior 
that other AD variants might be associated with proteins involved in this BP or 
proteins that physically interact with this BP.  This hypothesis can be tested 
computationally using a protein interaction network [40-42] by extending the “guilt 
by association” principle via propagation of probabilistic evidence in a network 
[43, 44].  This general idea has similarity to the Google ranking algorithm of web 
pages, in which a web page that has a short link distance to many “important” 
pages will itself be considered “important.”  
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In the case of protein interactions, guilt by association-based inference is 
typically performed by inspecting the function of direct neighbors of a predicted 
disease gene in a protein-interaction network.  This approach has been 
incorporated in multiple interpretation systems as well as commercially such as 
Ingenuity Pathway Analysis (IPA). However, it has been shown that network 
propagation, diffusion or other related methods that go beyond simple neighbor-
based analysis can carry functional or disease associations further in the network 
with improved predictive accuracies [37, 38]. This idea extends to predicting both 
gene function and disease phenotypes associated with genes [26, 27, 38, 45-47]. 
We hypothesize that this general framework, and network diffusion in particular, 
can be extended to aid prioritization of AD genes. Although the underlying 
biology of AD may be far more diverse than a single function, there are several 
biological pathways that are aberrantly activated in AD brains, and not 
surprisingly, most of the genes identified by AD GWAS contribute to these 
pathways [48]. For example, a primary indicator of AD is the accumulation of 
amyloid beta plaques in the brain, resulting from mis-processing of APP protein 
[48].  
We developed a novel re-prioritization approach that can be integrated easily into 
the current genetic analysis design (Figure 2.1). First, we curated the AD 
literature to produce a set of approximately 60 robust AD (RAD) genes that 
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includes those that have been associated with AD at the genome-wide 
significance level or that contain variants shown to affect AD-related processes 
directly (Table 2.1). We then constructed a network of protein-protein interactions 
and applied network diffusion to score and rank genes based on their proximity to 
the RAD genes. Network diffusion allows modeling of indirect interactions, 
modules and protein complexes that are not modeled if only the direct 
interactions of proteins are considered. Next, we combined our genetic 
association results with the network diffusion scores to produce a newly re-
prioritized ranking of genes. Finally, we validated our methodology using a novel 
approach involving bootstrap aggregation on one of the largest assembled 
genetic datasets of AD. Network-augmented genetic results have measurably 
improved replication rates in this validation approach. We also show that our 
main results and key predictions were essentially unchanged after restricting the 
RAD set to 19 genes which have had been functionally validated as well as 
replicated in independent datasets. 
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Figure 2.1: Summary of Analysis Steps. A set of AD genes that are 
reproducible (RAD genes) across different genetic studies was assembled 
through literature curation. The RAD genes were assigned a high initial risk 
score, and graph theoretical diffusion was employed to derive network diffusion 
scores for the rest of the genes in the network. Scores obtained from genetic 
screens and network diffusion were integrated to derive a new prioritization. 
9 
 
Table 2.1. RAD Genes and the Type of Study that Identified Them 
  
Chr. Gene Evidence Chr Gene Evidence Chr Gene Evidence 
1 CR1 GWAS – 
AD [35, 49] 
7 ZCWPW1 GWAS – AD 
[35] 
12 SRRM4 GWAS – 
endo [50] 
1 PSEN2 Linkage 
[51] 
7 EPHA1 GWAS – AD 
[52] 
13 SLCA10A2 GWAS – 
AD [35, 
53] 
2 BIN1 GWAS – 
AD [35] 
7 PLXNA4 GWAS – AD 
[54] 
14 FERMT2 GWAS – 
endo. [35] 
2 INPP5D GWAS – 
AD [35] 
8 PTK2B GWAS – AD 
[35] 
14 PSEN1 Linkage 
[51] 
2 CASP8 WES [55] 8 CLU GWAS – AD 
[49] 
14 SLC2A4A GWAS – 
AD [35] 
3 KCNMB2 GWAS – 
endo [56] 
8 TP53INP1 GWAS – AD 
[57] 
14 PLD4 GWAS – 
endo. [58] 
3 OSTN GWAS – 
endo [59] 
8 PDGFRL GWAS – 
endo [60, 61] 
15 TRIP4 GWAS – 
AD [62] 
4 UNC5C WES [63] 9 LMX1B GWAS – 
endo [64] 
16 PLCG2 GWAS – 
AD [65] 
4 GALNT7 GWAS – 
endo [56] 
9 MVB12B GWAS – 
endo 
17 MAPT GWAS – 
AD [66] 
5 MEF2C GWAS – 
AD [35] 
10 ECHDC3 GWAS – AD 
[61] 
17 KANSL1 GWAS – 
AD [66] 
5 SORCS2 CGS [36] 10 SORCS1 CGS [36] 17 ABI3 GWAS – 
AD [65] 
5 PFDN1 GWAS – 
AD [61] 
10 SORCS3 CGS [36] 17 ACE CGS [67] 
6 HLA-
DRB5 
GWAS – 
AD [35] 
11 CELF1 GWAS – AD 
[35] 
19 ABCA7 GWAS – 
AD [35] 
6 TREM2 WES [68] 11 SPI1 GWAS – AD 
[69] 
19 PLD3 WES [70] 
6 NCR2 GWAS – 
endo [59] 
11 MS4A6A GWAS – AD 
[35] 
19 APOE Linkage 
[71] 
6 CD2AP GWAS – 
AD [52] 
11 MS4A4A GWAS – AD 
[35] 
19 CD33 GWAS – 
AD [35, 
52] 
6 TPBG GWAS – 
AD [61] 
11 MSA6 GWAS – AD 
[35] 
20 CASS4 GWAS – 
AD [35] 
7 COBL GWAS – 
AD [53] 
11 PICALM GWAS – AD 
[49] 
21 APP Targeted 
Seq. [51] 
7 AKAP9 WES [72] 11 SORL1 CGS [35, 36] 21 ABCG1 GWAS – 
endo. [56] 
7 PILRA GWAS – 
AD [73] 
11 C1QTNF4 GWAS – 
endo [50] 
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Methods 
 
Assembling an AD Gene List 
A set of genes ascribed to AD with a high degree of certainty was assembled 
through curation of published findings ascertained through PubMed searches 
that emerged from studies using a variety of approaches including GWAS of AD 
risk and AD-related endophenotypes, family-based linkage analysis, positional 
cloning, whole exome sequencing (WES), and candidate gene testing (CGS) 
(Table 2.1). Criteria for inclusion in this set included (1) genome-wide 
significance for GWAS and WES studies (p < 5x10-8) and LOD score > 3 for 
linkage studies and (2) replication of association signals in independent datasets; 
or (3) biological evidence that demonstrate functional relevance to AD of 
associated variants or the encoded protein. 
Harmonizing Protein-Protein Interaction Databases 
A set of interacting gene-gene pairs (in HGNC symbol format) is required as 
input for this software. To compile this set, three databases (RefIndex v14 [41], 
ConsensusPathDB v31 [40], and Human Interactome Y2H DB vHI-II-14 [42]) 
were selected based on their demonstrated utility in recent work [27]. 
iREFINDEX and ConsensusPathDB interactions were filtered to remove self and 
complex (more than two proteins) interactions. The ConsensusPathDB 
interactions are given in uniProt ID format, which were converted to HGNC 
symbols using the official website (http://www.genenames.org). iREFINDEX 
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provides a HGNC symbol for each interactor of an interaction when possible, and 
so only interactions which had a HGNC for both interactors were kept. The 
Human Interactome DB already provides a set of binary gene-gene interactions 
in HGNC format, so no processing was required. The union of the processed 
sets from each database was used as the final interaction set. The unified set 
contains 19,972 unique gene symbols and 236,642 interactions. These 
databases are curated collections of experimentally determined interactions 
(typically binding or affinity) reported in the literature, such as from co-
immunoprecipitation, as well as predicted interactions in a small number of 
databases. 
Assigning Network Scores to Genes Through Diffusion 
Network diffusion is a very well-studied spectral approach to graph clustering and 
annotation [7, 44, 74, 75]. It attempts to mimic node-to-node distance in the 
graph that in turn aims to capture functional relevance. The first step of the 
diffusion method is to model the protein interactions as a network. A network is 
comprised of a set of nodes, V, and a set of edges between nodes, E. For this 
work, nodes represent genes, and edges represent an interaction present in the 
unified set. Although we use unweighted edges in this work, our network 
methods and software are able to receive weighted input as well, such as protein 
interactions with confidence measures taken from STRING [76]. The construction 
of diffusion kernels using weighted edges has been well studied and is equally 
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valid [74]. n is the number of nodes in the network, which is 19,972 (yielding 
236,642 edges). All network methods were implemented in R. The regularized 
Laplacian kernel [74] is constructed by: 
 = ( +  )
 
where K is the resulting kernel, I is the identity matrix, L is the graph Laplacian, 
and alpha is a constant ([74] for additional details). For this study, an alpha value 
of 0.1 was used, consistent with other work in this field [44]. Next, a network 
diffusion score was computed for each gene. To do this, the diffusion score 
vector, y, was initialized to be a length n vector that contains 1’s in the indices of 
the RAD genes, and 0’s otherwise. Risk scores for all genes in the graph were 
then derived by multiplication of K by the diffusion score vector y:  ỹ =  
Validation of Diffusion Using a Leave-One-Out Approach 
To test if RAD genes had closer than random diffusion proximity to other RAD 
genes in a network, leave-one-out cross validation [77] was applied to the RAD 
gene set. First, a single RAD gene from the RAD set was set to 0 in the initial 
diffusion score vector, y. Then, diffusion scores were computed based upon this 
new initialization of y. The diffusion scores were sorted and the sorted rank of the 
removed RAD gene’s diffusion score was determined in comparison to all other 
non-RAD genes. This process was repeated for each gene in the RAD set, 
resulting in a list of ranks. If diffusion proximity is informative and potentially 
predictive, the average rank of the RAD genes should be significantly lower than 
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the average rank of all genes, (n+1) / 2, which was verified using a one-tailed t-
test. 
ADGC GWAS Dataset 
The Alzheimer’s Disease Genetics Consortium (ADGC) is an NIA-funded project 
whose goal is to identify genes associated with an increased risk of developing 
late-onset Alzheimer disease (LOAD) by assembling and analyzing genetic and 
phenotypic data from large cohorts containing rigorously evaluated AD cases and 
cognitively normal controls of various ethnic ancestries.  Details of 
ascertainment, collection, quality control (QC), and analysis of genotype and 
phenotype data in the individual datasets of the ADGC are provided elsewhere 
[35, 78]. Here we examined genotype data that were generated using high-
density SNP microarrays from 32 prospective, case-control, and family-based 
studies of LOAD comprising 16,175 case and 17,176 controls of European 
ancestry. After QC steps to filter low-quality SNPs and individuals with low 
genotype call rates, principal components (PCs) of ancestry were computed 
within each dataset using EIGENSTRAT [79] and a set of 21,109 SNPs common 
to all genotyping platforms and datasets in order to account for population 
substructure in genetic association analysis. Samples with outlier PC values >six 
standard deviations from the mean were excluded from subsequent analyses. 
Genotypes for a much larger set of SNPs were imputed using the Haplotype 
Reference Consortium panel release 1.1 [80, 81], which includes 64,976 
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haplotypes derived from 39,235,157 SNPs, and the Michigan Imputation Server 
(https://imputationserver.sph.umich.edu/) running MiniMac3 [82, 83].   
Genome-wide Association Analysis  
Association of AD with the imputed dosage of the minor allele for each SNP (a 
quantitative estimate between 0 and 2) genome-wide was conducted using 
logistic regression models implemented in PLINK [84] that included covariates for 
age-at-onset/age-at-exam, sex, the first three PCs, and an indicator variable for 
each dataset. Joint analysis was chosen in favor of meta-analysis to avoid 
problems that could be introduced if bootstrap aggregation under-sampled small 
cohorts, resulting in unreliable association estimates for those cohorts. To 
account for relatedness in family datasets, subsets of maximally-unrelated 
affected and unaffected individuals were sampled from each pedigree. Each 
variant was annotated to a gene region according to RefSeq release 69 [85] 
using the program ANNOVAR [86]. Then, each gene was assigned the minimum 
p-value of all variants annotated to it, after applying the following formula: 
 = 1 −  (1 −  )  
where N is the number of variants analyzed that were annotated to the gene. 
Previously, this correction [87] has been shown to perform comparably to more 
complex adjustments based upon gene length, recombination hotspots, and 
similar gene features [88]. 
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Validation of Genetic Re-Prioritization Through Bootstrap Aggregation 
Since the availability of large AD genetic datasets is limited, bootstrap 
aggregation [89] was used to generate a high number of datasets for method 
validation. First, the full ADGC dataset was equally separated into discovery and 
replication halves. Then, 25 iterations of bootstrap aggregation were applied to 
the discovery half and then the replication half. The resultant 25 discovery and 25 
replication datasets were then matched (D1 and R1, D2 and R2...D25 and R25). 
To further ensure robustness, the splitting procedure was repeated a total of 5 
times, with 25 iterations of bootstrap aggregation applied each time, resulting in 
125 total pairings (D1 and R1, D2 and R2....D125 and R125). Each pairing 
represents a discovery dataset as well as an independent replication dataset. 
For each pairing, the previously described genetic analysis was conducted on the 
discovery half. Then all genes that passed a designated significance threshold 
(the number of passing genes is denoted as r) were selected to be tested again 
in the replication half using a significance threshold of (0.05 / r). The replication 
rate was computed by determining the percentage of passing genes in the 
discovery half that also passed in the replication half. A replication rate was 
estimated for each pairing, and the mean replication rate was then determined. 
Next, the replication rate was re-determined for each pairing, with the added 
criterion that selected genes must also have a top percentile network diffusion 
score (top 10th, 20th, 30th, 40th, and 50th were tested). The average replication 
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rate for each filtering threshold was compared to the average replication rate 
without filtering. 
Integrating GWAS and Network Diffusion Scores 
The p-values from genetic analysis of the ADGC dataset were converted to Z-
scores using the qnorm function in R. Then, the network diffusion scores were 
converted into percentiles. The percentiles are transformed into Z-scores using 
the qnorm function, with the additional specification of lower.tail=F. The weighting 
scheme from METAL was applied to combine the GWAS and network Z-scores: 
 !"#$ =  % ∗  '( + % ∗  ' )*+% + %
 
Although any weight selection can be used, the weights were “learned” using an 
SVM [90] due to the observation that the GWAS and network scores did not 
contribute equally to predicting replication rate. First, a replication rate was 
determined for each gene. If a gene had a p-value of <0.05 in d discovery 
datasets and a replication p-value of <0.05 in r of the paired replication datasets, 
it was assigned a replication rate of r/d. To reduce model overfitting, create 
sufficient separation between the classes, and achieve a balance of high and low 
replicating genes, only high replication genes (≥0.7, n = 676) and low replication 
genes (<0.1, n = 475) representing approximately 8.4% of the total genes with 
both a network and GWAS scores were extracted. By comparison, using a 
threshold of 0.8 or 0.9 would result in an imbalanced training set with very few 
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high replication genes because highly replicating genes are uncommon. A linear 
SVM [90] was trained using the network Z-scores and the genetic association Z-
scores as features, and “high” and “low” as the classes. The resulting slope of 
decision boundary was then used to determine appropriate weights (w1 = 0.703, 
w2 = 0.297). 
Pathway Analysis Using the Re-Prioritized Ordering of Genes 
Pathway enrichment was performed using the Gene Set Enrichment Analysis 
(GSEA) software [91]. GSEA’s pre-ranked analysis tool requires that the user 
provide a numeric measure for ordering genes. To establish a baseline, 
enrichment was done using our internal GWAS Z-scores to order genes. Then, 
enrichment was done using the alternative ordering genes based upon their 
combined Z-scores (see above for combination method). The gene sets tested 
for enrichment were the GSEA C2 pathways in MSigDb, which are the “curated 
gene sets” compiled from multiple sources including KEGG [92], Reactome [93], 
and domain experts. The significance threshold was set at FDR < 0.25, as 
suggested previously for this hypothesis generating approach [91]. 
 
Results 
 
RAD Genes Are Proximal in a PPI Network 
We assembled a PPI network using interactions pooled from multiple PPI 
databases (ConsensusPathDB [40], iRefIndex [41], and Human Interactome Y2H 
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[42]) inspired by recent work [27] . Pooling interactions from these three 
databases resulted in a connected network that includes a large percentage of 
the genes in our GWAS dataset. We then determined if the RAD genes are 
proximal within this network.  The first proximity measure tested was the average 
shortest path (ASP) distance [94]. The ASP distance between RAD genes, 
determined by a leave one out strategy (See Methods), is much smaller than 
would be expected by random chance (Table 2.2). One problem is that ASP 
distance between RAD genes and genes with many interactions (the number of 
interactions a gene has corresponds to its “degree” and high degree genes are 
considered to be hubs) tends to be small (Table 2.3). In this situation, all hub 
genes will be falsely predicted to be AD-related. Thus, we incorporated instead 
the Regularized Laplacian diffusion kernel [74] which penalizes paths going 
through hubs. The diffusion distance between RAD genes is smaller than would 
be expected by chance (p = 0.00054) (Table 2.2). Simultaneously, the 
problematic hub genes in the network have discounted scores as demonstrated 
by the notable drop in ranking of the 10 genes with the highest number of overall 
interactions (Table 2.3). 
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Table 2.2. Proximity Between RAD Genes in PPI Network. Each RAD gene 
was ranked (in comparison to the other 19,972 genes in the network) based upon 
its degree (number of interactions in network), its ASP distance to the RAD 
genes, and total diffusion distance from the RAD genes. The average ranking of 
the RAD genes was 7,949 using ASP (60th percentile, t-test p = 0.015) and 
6,959 for diffusion (65th percentile, t-test p = 0.00054). 
 
 
  
Gene Degree ASP Diffusion Gene Degree ASP Diffusion Gene Degree ASP Diffusion
APP 2 2 1248 MEF2C 3012.5 3072.5 2619 SORCS2 12984 14902.5 1081
CASP8 238.5 76 754 ABI3 3012.5 10739 3228 SORCS3 14153 16106.5 1170
PSEN1 558.5 119.5 441 SORL1 4372.5 9964 2675 ABCG1 14153 7689.5 16627
MAPT 600.5 9 342 TPBG 4516.5 4551.5 5100 TP53INP1 14153 11727 10975
PTK2B 800 175 670 PDGFRL 4862 13192.5 7434 PLXNA4 14153 15296.5 14933
CLU 883 785 1935 LMX1B 5236.5 10441.5 7905 KCNMB2 15703.5 11038.5 12216
PFDN1 930.5 2268 4465 HLA-DRB5 5666.5 4554 7104 SORCS1 15703.5 17153 9425
CD2AP 1043.5 2275.5 585 CD33 5666.5 2281.5 1682 MS4A6A 15703.5 19883.5 19955
PSEN2 1188 454 642 PLD3 5891.5 4554.5 4320 ABCA7 15703.5 7689.5 17609
AKAP9 1230 4547.5 2996 CELF1 5891.5 789 3793 SRRM4 18290 18462.5 18934.5
PLCG2 1255 281 868 PILRA 6640.5 13274.5 8762 CASS4 18290 14847.5 16647.5
APOE 1517 283 626 CR1 7296.5 15652 12460 ECHDC3 18290 19700.5 19390
INPP5D 1582 455 795 GALNT7 7296.5 7688 8782 PLD4 18290 7689.5 17433
BIN1 1691 457 977 MVB12B 7995.5 7688.5 4498 TREM2 18290 19587 1566
TRIP4 2509 4548.5 5679 ACE 8878 4555 9212 SLC10A2 18290 7689.5 17128
PICALM 2640 3070.5 1207 EPHA1 9380.5 7689 8437 ZNF804B 18290 18465 18406
KANSL1 2780 3069.5 3734 COBL 9928.5 13930 9416 NCR2 18290 19587 1566
FERMT2 2857.5 1496.5 3313 UNC5C 12984 14796.5 15064
Rank Rank Rank
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Table 2.3. Proximity of Non-RAD Hub Genes to RAD Genes. The resulting 
ranking each hub (high degree) gene received when propagating from the RAD 
genes using both ASP and then Diffusion was determined. Hub genes tended to 
have top 50 rankings under ASP, whereas diffusion more appropriately penalized 
the high degree of the hubs to allow lower degree genes to rank higher. 
 
  
Gene Degree ASP Diffusion
UBC 1 1 1433
SUMO2 2 20.5 1570
CUL3 3 51 2515
SUMO1 4 20.5 1502
EGFR 5.5 3 937
TP53 5.5 7 983
GRB2 7 2 905
SUMO3 8 181 2433
HSP90AA1 9 10 978
MDM2 10 51 1096
Rank
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Filtering by Network Diffusion Score Improves Replication Rate 
We next tested if genes with high diffusion scores replicate more frequently in 
order to demonstrate that diffusion scores are informative when used in 
conjunction with genetic data. Bootstrap aggregation [89] was applied to our 
genetic dataset to produce a large number of pairs of discovery and replication 
datasets (See Methods). In each discovery + replication pair, we conducted a 
standard genetic workflow, beginning with a screen in the discovery dataset 
followed by validating top findings in the replication dataset. For each pair, a 
replication rate was calculated by determining the percentage of genes that 
surpass a given significance threshold also replicated. To test if network diffusion 
scores improved replication, we altered the standard discover + replication 
approach. We ranked genes by their network diffusion score and then iteratively 
dropped genes that had ranking diffusion scores below a given stringency 
threshold. At first we retained only genes in the 50th percentile of network 
scores, then gradually increased the threshold to only include genes in the 60th, 
70th, 80th, and 90th percentiles. For each threshold, we computed the replication 
rate and compared to the baseline. As shown in Figure 2.2, filtering based upon 
network score percentile noticeably increased replication rate. Genes with a –
log(p-value) of > 6 replicated at a rate of approximately 16% in simulations 
(farthest right purple point), while additional strict network filtering improved the 
replication rate to nearly 34% (farthest right red point).  
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Figure 2.2: Filtering on Network Score Improves Replication Rate. The 
replication rate was computed for all genes surpassing the significance threshold 
for each GWAS. This procedure was repeated in each bootstrapped dataset and 
the average replication rate was determined (purple). This process was repeated 
using increasingly strict filters on the network diffusion scores. The baseline 
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replication rate without utilizing network scores (naïve method) is represented by 
the purple points. The strictest network filter (red) has a consistently higher 
replication rate than the naïve method.  
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Combined Z-Scores Predict Novel AD Genes  
Since filtering on network diffusion score improved replication rate, we next 
sought to integrate the network diffusion scores and genetic results into a single 
score. First, we converted the p-value of each gene from genetic analysis into a 
Z-score (“GWAS Z-Scores”) and then converted the network diffusion percentile 
of each gene into a Z-score (“Network Z-scores”). Linear regression analysis 
showed that the Network and GWAS Z-scores are independent (Figure 2.3A). 
Next, we assigned each gene a replication rate based upon how frequently the 
gene replicated in our bootstrapped validation datasets (See Methods). We 
observed that replication rates were higher for genes with higher network Z-
scores compared to genes with lower network Z-scores (Figure 2.3B). 
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Figure 2.3: Comparison of GWAS and Network Z-Scores. A. Transformed Z-
scores are uncorrelated. B. Genes with high network scores had higher 
replication rates compared to those with low network scores, as further visualized 
and confirmed statistically as shown in Figure 2.4. Reprate = replication rate. 
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To combine the Network and GWAS Z-scores, we developed an approach that 
uses a linear support vector machine (SVM) [90] to determine how heavily each 
type of score should be weighted in order to maximize replication rate (See 
Methods). These weights were then used in conjunction with the meta-analysis 
method for combining summary results implemented in METAL [95]. The weights 
predicted by the SVM (Figure 2.4) were 0.703 (GWAS) and 0.297 (Network). As 
further confirmation, we conducted binomial (logit family) logistic regression using 
network and GWAS Z-scores as predictors and the replication class (high/low) as 
the outcome. Both network and GWAS score were significant, (GWAS: 
coefficient = -0.659, p <2.0×10-16) (Network: coefficient = -0.229, p = 0.0016). 
The coefficients derived from logistic regression are very similar to the SVM-
derived weights (GWAS weight = 0.742, Network weight = 0.258). 
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Figure 2.4: Support Vector Machine Training to Predict GWAS and Network 
Z-Score Weights. Selection of genes with a high replication rate (> 0.7, blue 
points) and low replication rate (<0.1, red points) yielded a balanced number of 
genes in each replication class (high/low). A linear SVM model was trained to 
predict replication class using the GWAS and network Z-scores of each gene. 
Both network and GWAS Z-scores contributed to the decision boundary, as 
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demonstrated by the significance of their predicted coefficients using logistic 
regression (GWAS: p <2.0×10-16, Network: p = 0.0016). 
Next, we applied our combined approach genome-wide, excluding the RAD 
genes and genes containing significantly associated variants (p <1.0x10-7) to 
focus on novel candidates. Among the genes with largest combined Z-scores 
(Table 2.4), several have important roles in inflammation. CR2 (p = 5.95×10-7) is 
a receptor protein involved in immune response (genecards.com [96]). SHARPIN 
(p = 1.43×10-5) is a component of the LUBAC complex that plays a regulatory 
role in inflammation [96]. PTPN2 (p = 3.21×10-5) is a phosphatase that also 
serves an important role in regulation of inflammation and glucose homeostasis 
[96]. The Bonferroni-corrected significance threshold when considering only 
genes in the 75th percentile of network scores is p = 1.46 x 10-5, although this is 
likely to be overly strict since proximally located genes are not inherited 
independently. 
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Table 2.4. Top Predicted AD Genes Using Combination Approach. The 
GWAS and Network Z-scores were combined into a single Z-Score using the 
weights determined by the SVM. The top 10 ranking genes are depicted in the 
table.  
 
  
Gene GWAS Network Combined
CR2 4.084 2.832 4.857
SHARPIN 3.983 1.320 4.185
PTPN2 3.805 1.259 3.997
C4B 2.846 2.928 3.750
TUBB2B 3.166 1.314 3.428
EPS8 3.156 1.156 3.358
PSMC3 3.145 1.036 3.302
STRAP 3.051 1.157 3.262
HSPA2 2.977 1.325 3.258
STUB1 2.895 1.407 3.213
Z-Score
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We performed pathway analysis using Gene Set Enrichment Analysis (GSEA) 
[91] to determine if AD-related pathways are more enriched when genes are 
ranked by their combined Z-scores versus GWAS-only Z-scores (See Methods). 
Notably, ranking genes based upon combined Z-scores resulted in several 
significantly enriched AD-related pathways including immune response, FOX03 
targeting (indicates enrichment for aging), and hippocampal development (Table 
2.5). By comparison, ranking genes based only upon their GWAS Z-scores 
resulted in virtually no significant pathways entirely (Table 2.6). 
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Table 2.5. GSEA Results After Ranking Genes by Combined Z-Scores. 
 
 
Table 2.6. GSEA Results After Ranking Genes by GWAS Only Z-Scores. 
 
  
NAME SIZE ES NES FWER p-val
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION 64 0.487289 2.230758 0.042
DELPUECH_FOXO3_TARGETS_DN 37 0.527147 2.180592 0.07
BIOCARTA_PGC1A_PATHWAY 20 0.612627 2.179728 0.071
KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS 85 0.436425 2.171402 0.073
MURAKAMI_UV_RESPONSE_6HR_DN 20 0.592367 2.123952 0.117
GOLUB_ALL_VS_AML_DN 18 0.628548 2.118205 0.127
REACTOME_RNA_POL_I_PROMOTER_OPENING 28 0.551692 2.099766 0.149
MODY_HIPPOCAMPUS_PRENATAL 36 0.519005 2.097922 0.153
FARMER_BREAST_CANCER_CLUSTER_5 17 0.632376 2.089917 0.161
ZUCCHI_METASTASIS_DN 35 0.516274 2.066772 0.197
NAKAYAMA_SOFT_TISSUE_TUMORS_PCA1_UP 61 0.456125 2.058099 0.205
INGA_TP53_TARGETS 15 0.635151 2.049176 0.222
NAME SIZE ES NES FWER p-val
NAKAYAMA_SOFT_TISSUE_TUMORS_PCA1_UP 61 0.4396 2.108 0.134
FARMER_BREAST_CANCER_CLUSTER_5 17 0.6101 2.016 0.261
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION 64 0.3975 1.95 0.418
GOLUB_ALL_VS_AML_DN 18 0.5596 1.888 0.591
CHIARETTI_T_ALL_REFRACTORY_TO_THERAPY 23 0.499 1.879 0.608
SHIN_B_CELL_LYMPHOMA_CLUSTER_5 15 0.541 1.772 0.864
ZUCCHI_METASTASIS_DN 35 0.4231 1.769 0.873
KIM_HYPOXIA 22 0.4561 1.704 0.964
DELPUECH_FOXO3_TARGETS_DN 37 0.3995 1.672 0.985
NIELSEN_LIPOSARCOMA_UP 15 0.5139 1.65 0.993
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Discussion 
 
GWAS of AD and AD-related endophenotypes have discovered and replicated 
associations with more than 60 genes (Table 2.1), many of which have roles in 
AD-related pathways (amyloid β aggregation, inflammation, cholesterol transport, 
immune response, etc.). To identify additional AD-related genes, we 
hypothesized that genes having suggestive evidence for association from a 
genome-wide screen and protein-level interactions (both direct and indirect) are 
more likely to replicate. This idea has been referred to as functional linkage [97]. 
To test this hypothesis, we developed a novel approach for improving the 
prioritization of candidate disease genes that incorporates a network diffusion of 
scores from known disease genes using a protein network and integration with 
GWAS risk scores. We tested this approach on a large AD GWAS dataset and 
validated the performance of the methodology using bootstrap aggregation. 
Several novel AD genes were predicted including CR2, SHARPIN, and PTPN2. 
Part of the motivation for our approach was to identify genes that are more 
obviously biologically relevant to AD. This is exemplified by SHARPIN, whose 
principal known function is to form the LUBAC complex and prevent 
inflammation, a major process through which amyloid aggregation and AD are 
thought to develop [48]. Similarly, CR2, a homolog of CR1 which is a well-
established AD gene [35], is involved in immune response. Many immune 
response genes are differentially expressed between healthy and AD brains, and 
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investigations into the connection between expression in cell types and the 
presence of AD has led to growing interest in the role microglial cells (a first 
responder in the immune response pathway) [98]. Finally, PTPN2 is involved in 
multiple AD-related pathways; it has roles in negatively regulating inflammation 
and de-phosphorylation of key glucose metabolism kinases including INSR and 
EGFR [99]. The AD-related roles of each of our novel AD gene predictions, in 
combination with their strong network and genetic scores, make them highly 
promising candidates.  
One biological form of functional linkage that does not require direct physical 
interaction is membership in the same signaling pathway or protein complex. For 
example, our study identified interaction between FOXO and INSR that is 
consistent with evidence of a multi-link signaling pathway comprised of direct 
physical interactions in the insulin-signaling pathway [92]. By comparison, 
neighborhood enrichment approaches (i.e., testing a gene’s direct interactions) 
cannot detect indirect interactions. Furthermore, neighborhood enrichment 
approaches are unreasonable for AD because some RAD genes are network 
hubs (e.g., APP has more than 2000 interactions) which would result in an 
unreasonably high number of genes having AD-enriched neighborhoods. 
Some distance metrics capture indirect interactions by calculating the proximity 
between a pair of genes based upon short paths between them in the network. 
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However, after testing a simple distance metric known as average shortest path 
(ASP), we observed that hub genes were still the top-ranked predicted genes. 
Since hub genes have many interactions, they tend to have short overall paths to 
any genes in a network, although their functions are highly generic and unlikely 
tied to a particular disease. Ubiquitin C (UBC), for example, has nearly 9,000 
interactions; however, this is simply because protein degradation is essential for 
regulating the vast majority of proteins. Therefore, a more nuanced network 
propagation approach can aid in making disease specific inferences.  
Network diffusion is a widely used class of spectral graph clustering methods that 
have been applied to many computational disciplines [74].  We used this 
approach to propagate evidence in the form of AD scores throughout the 
network. A protein in the network that has a short “diffusion distance” to one or 
more well-established AD genes will receive a high network risk score. Notably, 
we observed that network diffusion down-weights hubs while simultaneously 
outperforming ASP distance when applying leave-one-out cross-validation to the 
RAD genes. Many diffusion kernels have been proposed in graph theory, 
however the Regularized Laplacian [74] approach used in this study has the 
highly desirable properties of requiring very little parameterization (in fact, only a 
single parameter is required to be set) and also more computationally efficient 
than other diffusion kernels. Network diffusion methods have been applied in 
other genetics research contexts such as labeling somatic network mutations in 
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cancer [100], characterizing gene sets [101], and predicting risk genes for 
amyotrophic lateral sclerosis [27].  
We also observed that genes with high diffusion scores tended to replicate more 
frequently in our 125 pairs of bootstrapped discovery and replication datasets. 
However, network Z-scores and GWAS Z-scores in the full dataset were not 
strongly correlated. Taken together, these observations indicate the importance 
of considering jointly protein interaction data and genetic results even though 
they are independent because the integration of both types of information will 
likely yield noticeable improvement in replicability of findings. Since our 
bootstrapping procedure required splitting the original dataset, the simulations 
were conducted using datasets that contained only one-half of the total sample. 
This suggests that our network scores aided in determining which genetic 
associations were real in datasets with reduced power. We note that our 
bootstrapping approach was performed on the same data from which we derived 
the GWAS Z-scores used to train the SVM. Therefore, the selection of 
combination weights may have been biased in favor of GWAS Z-scores. 
Furthermore, it is unclear whether the weight combination used in this study 
(0.297/0.703) would be appropriate for combining genetic and network data for 
other disorders or traits.  
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The GWAS approach has a very limited capability to identify the entire set of 
genes which contribute to the risk of a complex disease like AD, even in datasets 
containing up to 100,000 individuals, because some genes do not contain 
variants that are sufficiently frequent and/or exert a large enough effect to yield a 
statistically significant association. To overcome this limitation, we developed a 
novel SVM approach to integrate the genetic and network scores by propagating 
GWAS Z-scores in a PPI network. In the AD example presented here, we 
initialized the RAD genes to have an identical high score in the network, thereby 
allowing re-prioritization of genes in any AD dataset regardless of the internal Z-
scores of the RAD genes.  
We acknowledge that our initial choice to treat each RAD gene equally may be 
controversial. Arguably, we could have seeded our analyses with GWAS Z-
scores for each RAD gene from the original studies. However, our approach 
permits unbiased exploration of interactions of all plausible AD genes and does 
not require adjustment to these Z-scores for sample size or allele frequencies. 
Moreover, results derived from weighted RAD genes would be dominated by 
interactions with APOE for which the significance level exceeded a –log(p-value) 
of more than 100 in several datasets (compared to < 10 for most other RAD 
genes in the total group of datasets. Also, several key AD-related genes (e.g., 
APP, PSEN1 and PSEN2) which show little evidence for association with 
individual SNP or gene-based tests for AD would be undervalued in analyses 
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using weighted Z-scores. In order to make our software maximally flexible and 
support weights derived from confidence in the seed genes, we implemented an 
option for users to specify unequal weights on the seed genes at their own 
discretion.  
A potential concern about our results is the strategy for selecting RAD genes 
because many significant GWAS findings include variants located in intergenic 
regions. The most parsimonious explanation is that the variant responsible for 
the association peak influences the nearest gene, but there is abundant evidence 
suggesting this assumption is often incorrect. To address this issue, we repeated 
our analyses using a more restricted set of RAD genes that included only those 
supported by genome-wide significant evidence of association with AD risk and 
replication in independent datasets or by other genetic evidence plus 
experiments linking them to AD-related pathophysiology. Our leave-one-out 
cross validation approach demonstrated that the genes in the restricted RAD set 
had closer network proximity to each other than would be expected by chance (p 
= 5.932e-05). The statistical support for the novel genes CR2 (p=4.09x10-7), 
SHARPIN (p=1.10x10-5), and PTPN2 (p=2.41x10-5) remained the same. Finally, 
combined Z-scores that were derived using diffusion from the more conservative 
RAD gene set yielded similar AD-related pathways such as Fx03 targets (FWER 
p=0.064), antigen processing (FWER p=0.02), and hippocampal development 
(FWER p = 0.065). These results confirm that the genes with a clear functional 
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role in AD produce network diffusion-based predictions that are consistent with 
the results presented here. Curiously, the inclusion or exclusion of the portion of 
RAD genes that have an ambiguous or non- validated functional role in AD did 
not affect our results.  
We also acknowledge that several of the novel putative AD genes may have 
been erroneously prioritized because they are in the same locus with RAD 
genes. This concern is unlikely noting that there are several instances where a 
genetic association peak includes multiple genes that may have a possible 
functional role in AD (e.g., the MS4A gene cluster [35]). Although one of our 
novel AD genes, CR2, is located close to CR1, which is an unambiguous RAD 
gene given its robust replication in GWAS and effect on deposition of neuritic 
amyloid plaque, CR2 is also an intriguing AD candidate gene because it has 
been shown to regulate hippocampal neurogenesis [63]. Thus, our findings 
suggest that our approach will aid in predicting truly multiple AD-related genes at 
a locus, however additional biological evidence may be required in some 
instances to make this distinction. 
Previous AD studies have implicated inflammation and immune response genes, 
but we did not observe any enrichment for these pathways when using the 
GWAS-only scores in our dataset. However, these and other known AD-related 
pathways emerged after applying our network re-prioritization method (Table 2.6) 
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suggesting that incorporation of network data can help minimize discrepancies in 
predictions across different genetic datasets. However, a few well-established 
AD-related pathways were not detected by our analysis including cholesterol 
metabolism and endocytosis. Upon further investigation, enrichment for the 
cholesterol homeostasis pathway is not significant when applying GSEA to the 
genetic data only (FWER p = 1). The cholesterol homeostasis pathway as 
defined in MSigDB is general and therefore contains a high number of genes with 
weak associations to AD that diminish the enrichment of the set. The evidence 
for this pathway is greater in the analysis using only network scores (FWER p = 
0.18), which indicates our method still improves the detection cholesterol 
homeostasis. We do however replicate enrichment for the HDL mediated lipid 
transport pathway using only our genetic data (FDR q = 0.11), but this is primarily 
driven by a strong signal from APOE. The seed genes from the network analysis, 
such as APOE, need to be ignored to prevent bias, and therefore the lack of 
enrichment of the HDL mediated lipid transport pathway after applying our 
network approach is simply explained by the removal of APOE. 
It should also be noted that a simply connected network is a requirement for the 
diffusion algorithm to work properly.   
Our approach offers several advantages in comparison to other network-based 
approaches including biological transparency, ease of integration with a variety of 
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GWAS methods, and the ability to balance data-driven statistics and biological 
prior probabilities. The extensive simulations we conducted provide a general 
basis for further establishing the practicality of genetic and network-based 
integration. Our network methodology is specifically developed with the goal of 
accommodating known complications of genetic analysis. 
The software developed for this study is open source, accessible to most users 
(incorporated in an R package), and applicable to any set of variant- or gene-
level disease association results. Importantly, it requires only a set of GWAS 
results and a list of previously known disease genes and, therefore, does not 
necessitate changes to previously established genetic analysis pipelines. 
Although we used an SVM procedure to determine the weights for the score 
combination, a user can specify any weights or simply use our defaults that are 
based on the 0.297/0.703 ratio determined by SVM. Our package is accessible 
through GitHub (https://github.com/lancour/ignition).  
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Chapter 3: Analysis of Brain Region-Specific Co-Expression Networks 
Reveals Clustering Properties of Genes Associated with Alzheimer Disease 
Risk and Identifies Novel Risk Gene Candidates 
 
Neurodegenerative (ND) diseases, such as Alzheimer disease (AD), Parkinson 
disease (PD), Huntington disease (HD), and amyotrophic lateral sclerosis (ALS), 
impair or damage neurons. Although many sub-cellular similarities between NDs 
have been identified [102], the regional differences between them are quite 
profound [103-106]. For example, neuronal cell death from HD is primarily 
localized to the basal ganglia, whereas both AD and PD result in cell death 
throughout the brain [106]. Furthermore, PD causes the most severe cell death in 
the substantia nigra [103] whereas AD most heavily affects the hippocampus, the 
frontal cortex, and the temporal lobe [105]. These studies highlight the 
importance of studying gene expression signatures and relationships of AD-
associated genes in different brain regions. For instance, an increased 
correlation in gene expression among two AD-associated genes in brain 
structures such as the cortex as compared to other brain regions suggests either 
a functional relationship or cell/sub-region specific expression biases towards cell 
types where the disease tend to originate or progress most rapidly.  
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Altered functional connectivity between brain regions has been demonstrated for 
several neuropsychiatric diseases including schizophrenia, depression, and AD 
using functional magnetic resonance imaging (fMRI) [107-109]. Brain imaging 
and neuropathological studies indicate that the hippocampus, which has a role in 
memory formation, is one of the first structures showing marked neuronal loss in 
AD and, compared to other regions, suffers the largest relative reduction in 
volume by the latter stages of the disease [110]. Regional specificity is also 
evident by longitudinal patterning of the AD-related tau and amyloid-β proteins 
that aggregate into neurofibrillary tangles and senile plaques, respectively [111]. 
In the early stages of AD, a small number of tangles typically form in the brain 
stem, and then spread aggressively to most of the cerebrum by the latest stage. 
Amyloid plaques form in the opposite pattern, beginning primarily in the outer 
cortex and spreading inward and then to the brain stem [111]. Notably, very few 
protein aggregates form in the cerebellum even at the most severe stages of AD. 
  
The aforementioned differences in AD severity between regions of the brain may 
be a consequence of a variety of factors. One such factor is the tissue specific 
expression patterns of genes throughout the body, which is a relevant 
consideration for the human brain given its vast complexity and 
compartmentalization [112]. An additional factor may also be the changing cell 
type fractions observed between major regions of the brain [113, 114]. Large 
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scale multi-omic approaches have been able to assist in understanding these 
complicated roots of neuropsychiatric disease [115, 116]. Furthermore, they have 
been able to identify novel disease-related gene candidates [27, 117, 118]. 
 
In this study, we applied network-based correlation methods to existing genome-
wide association study (GWAS) data and gene expression data derived from 
brain in order to identify additional AD-related genes using network methodology. 
In addition to identifying several novel biologically relevant genes for AD, we 
show that the strength of correlations among previously established AD genes 
increases when the networks are restricted to the sub-regions of the brain that 
are most impacted by AD. 
 
Methods 
 
Acquisition of GWAS Data and Curation of AD Genes 
We obtained summarized results from a GWAS for AD risk conducted using 
16,175 AD cases and 17,175 controls of European ancestry that were derived as 
previously described [119]. Association evidence with each gene was derived 
from P-values for association with individual single nucleotide polymorphisms 
(SNPs) corrected for multiple testing using an approximation that has been 
shown to be a conservative adjustment for recombination hotspots, linkage 
disequilibrium, and gene size [88]. This correction can be expressed as  
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where N is the number of SNPs existing within a gene. Analyses for this study 
were also predicated on a group of reproducible AD (RAD) genes which were 
previously curated from the literature [119]. 
Acquisition, Labeling and Processing of Brain Expression Data 
Measurements of gene expression in the human brain were acquired from the 
Allen Brain Atlas (ABA). This database contains microarray data from 3,702 
single tissue samples extracted from six neuropathologically healthy brains (ages 
24, 26, 31, 39, 49, and 57). Data derived from each sample consists of an 
expression vector containing expression measurements from 45,000 probes in 
the extracted tissue. Each sample was annotated at three different levels of 
granularity, which are defined for the purpose of this study as low, mid, or high 
level structures in terms of region specificity. Principal components of the 
expression vectors across all samples were computed using the prcomp method 
from the R programming package [120]. Then each sample was annotated 
according to brain region based on the hierarchical labeling scheme described 
above. A scatterplot of the first and second principal components (PCs) was 
produced to ascertain whether the expression vectors of samples displayed 
batch effects related to either the region or the brains from which samples were 
derived. 
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Determining Gene Expression Within Each Brain Region 
Because some genes are queried by multiple probes, the mean expression of all 
probes mapping to each gene was computed, resulting in a gene x sample 
expression matrix. Expression of each gene in each brain region was adjusted 
using a mixed model approach to account for  repeated sampling of both 
individual brains and regions in the ABA dataset [121]. Each gene has an 
expression vector, E, of its expression levels in each sample. Each sample has 
an indicator of the region and the brain it was taken from. The model 
specification in R is then:  
E ~ -1 + region + (1 | brain) 
The region coefficients of this model represent a single gene’s expression in 
each of the 232 low level regions. This model is used for each individual gene, to 
ultimately determine each gene’s expression within each of the low level regions 
ascertained in the ABA dataset. 
 
Construction of Region-Specific Brain Co-Expression Networks 
We constructed a co-expression network based upon correlations between all 
pairs of genes across the cerebrum, cerebellum, and the brain stem. In this 
instance, each node of the network is a gene and each edge between genes is 
the absolute value of the Pearson correlation coefficient between a pair of genes. 
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Due to the high impact of AD on the cerebrum, two additional correlations 
networks were created by subdividing the cerebrum into two non-overlapping 
subsets of regions representing Braak stages [122]. In total, there were 79 
regions of the cerebrum in the ABA dataset that showed some evidence of AD at 
Braak stage 1, which we refer to as the early stage regions, and 37 regions of the 
cerebrum that showed more pronounced AD pathology at Braak stage 3, which 
we refer to as late stage regions. Correlations between all gene pairs were 
computed separately for early and late stage regions. In order to compare 
correlations between sets of genes of interest across networks, we normalized 
the correlations within each network.  For this we applied a novel metric, referred 
to as median ranking by correlation (MRC), that is derived using a “leave one 
out” strategy to normalize the distribution of correlations into a uniform 
distribution of ranks that is comparable across networks. Let RAD be the set of 
RAD genes and let G-RAD be the set of other genes.  
1. For each gene Gi in RAD let RAD-Gi be the set of genes in RAD different 
from Gi. For each Gi we compute the total sum of the correlations of Gi to 
the other genes in RAD(RAD-Gi). We refer to this as SUM-COR(Gi, RAD-
Gi).  Now for each gene Gj in G-RAD (genes outside the RAD set) we 
compute the full distribution of sum of correlations to genes SUM-
COR(Gj,RAD-Gi).  
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2. Let the Rank(G,RAD-Gi) be the rank of SUM-COR(Gi, RAD-Gi) in the full 
distribution of SUM-COR(Gj,RAD-Gi). 
3. Let MRC be the median such rank.  
If a gene set is clustered, the median of these rankings (MRC) of the RAD genes 
will exceed the expectation of 0.5.  
 
Verifying Consistency of Gene Rankings Across Correlation Networks 
Due to the small number of brain specimens in the ABA dataset, we tested the 
consistency of gene rankings by constructing a gene x gene correlation network 
for each brain. This procedure uses the same correlation approach described 
above, except that the expression levels of genes in each region were 
determined based on measurements from a single brain at a time. Next, each 
non-RAD gene was ranked by its correlation (RC) to the RAD seed genes within 
each of the six individual correlation networks. Finally, a Kendall Tau rank 
correlation matrix was derived based upon all possible combinations of these six 
ranked lists. 
 
Network-Based Ranking of Novel AD Genes 
Based on the observation that the RAD genes tend to be highly correlated, we 
hypothesized that other genes showing high correlation with established AD 
genes are likely to be AD-related genes. Therefore, a summed absolute Pearson 
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correlation with all the RAD genes was computed for each non-RAD gene. Next, 
a percentile rank of each non-RAD gene based upon these sums was computed 
and converted to Z-scores, which we refer to as network scores. If N genes are 
being ranked, then the percentile rank for each gene is: Percentile = (rank) / 
(N+1), ranging from 0 to 1. These percentiles form a uniform distribution, which 
are converted to Z-scores using qnorm(Percentile, lower.tail = F) in R. These 
network scores were then combined with genetic association Z-scores derived by 
a GWAS for AD risk including approximately 30,000 individuals using a 
combination procedure from the meta-analysis tool METAL that was modified to 
equally weight both scores [95]: 
 !"#$ =  0.5 ∗  '( + 0.5 ∗  ' )*
10.5 +  0.5
 
Further ranking was performed by integrating phenotypic information from gene 
orthologs in Flybase to focus on genes which when knocked out in a model 
organism result in an AD-related phenotype including premature aging, defective 
memory, defective aging, and oxidative stress [123].  
 
Results 
 
Principal component analysis did not reveal any batch effects related to sub-
region or brain specimen, however clustering of the samples was observed due 
to high level brain structure resembling the cerebrum, cerebellum, and brain stem 
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(Figure 3.1). The extent to which these samples are similar cannot be exactly 
determined with a PCA approach since the expression of many genes is not 
independent, but the clustering we observed suggests the presence of a batch 
effect. Further analysis revealed that RAD genes tended to have homogenous 
expression in the cerebellum and brain stem regardless of the changes in the 
mid-level structure (Figure 3.2). However, expression of these genes was highly 
variable across mid-level structures in the cerebrum. 
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Figure 3.1: Principal Component Analysis Indicates Clustering by High 
Level Structure. The principal components were computed for all samples in the 
dataset. Clustering was checked for low level structure, individual, and high level 
structure. Only high level structure, as labeled here, appeared to form clusters in 
the principal component plot (CX = cerebrum, BS = brain stem, CB = cerebellum) 
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Figure 3.2: RAD Genes Have Region-Specific Expression Levels. 20 of the 
commonly studied RAD genes were input into a heatmap clustering model. The 
RAD genes appear to cluster by high level structure (hst), which matches our 
expectation from the PCA. The brainstem and the cerebellum tend to have 
homogenous expression for individual genes, whereas the cerebrum has highly 
varied expression across mid-level structures (mst’s). 
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Comparison of co-expression of RAD genes across high level brain regions 
revealed higher correlation ranks (RC) in the cerebrum (0.748) than in the brain 
stem (0.648) and cerebellum (0.574, Table 3.1). These differences appear to be 
due largely to a few genes including APOE and MAPT which showed much 
greater co-expression in the cerebrum (RC = 0.745 and 0.863 respectively) than 
in the cerebellum (RC = 0.280 and 0.542, respectively) and brain stem (RC = 
0.216 and 0.337, respectively). Surprisingly, the RC for APP was much higher in 
the cerebellum (0.99) than in the brain stem (0.505) and cerebrum (0.376). 
Multiple RAD genes including PSEN2, EPHA1, LMX1B, TPBG, CLU, AKAP9, 
ZNF804B, PDGFRL, and ABCA7 were not meaningfully co-expressed with other 
RAD genes in any of the structures. 
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Table 3.1. RC of RAD Genes in the Cerebrum, Cerebellum, and Brain Stem. 
The RC of each of the RAD genes was computed in each of the correlation 
networks for each high level structure. From these, the MRC is computed and 
determined to be highest in the cerebrum (MRC = 0.749) in comparison to the 
cerebellum (MRC = 0.574) and brain stem (MRC = 0.648). Genes are ordered in 
the table based upon the variance of their RC across the three structures. 
Highlighted rows are examples of well-established AD genes that have 
dramatically different RC between brain structures. 
  
Percentile Ranking by Correlation 
Gene Brain Stem Cerebellum Cerebrum 
ZCWPW1 0.991 0.080 0.783 
TRIP4 0.997 0.226 0.772 
SORCS1 0.076 0.602 0.807 
OSTN 0.753 0.196 0.858 
PLXNA4 0.182 0.601 0.854 
SORCS2 0.785 0.136 0.605 
CASP8 0.222 0.720 0.853 
AKAP9 0.541 0.877 0.214 
APP 0.505 0.990 0.376 
ABCG1 0.392 0.325 0.897 
TP53INP1 0.880 0.394 0.968 
PFDN1 0.557 0.998 0.406 
COBL 0.902 0.323 0.662 
APOE 0.216 0.280 0.745 
SORCS3 0.134 0.376 0.706 
EPHA1 0.219 0.739 0.294 
ACE 0.778 0.667 0.249 
CR1 0.068 0.344 0.603 
MAPT 0.337 0.542 0.863 
KCNMB2 0.021 0.530 0.401 
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CLU 0.732 0.582 0.219 
PDGFRL 0.634 0.395 0.126 
PLD4 0.948 0.463 0.770 
SORL1 0.935 0.462 0.612 
CD2AP 0.351 0.691 0.772 
GALNT7 0.390 0.823 0.699 
SLC10A2 0.329 0.224 0.640 
PILRA 0.601 0.896 0.494 
CASS4 0.040 0.204 0.438 
PLD3 0.536 0.355 0.752 
MS4A6A 0.603 0.623 0.934 
C1QTNF4 0.804 0.714 0.451 
MS4A4A 0.728 0.499 0.859 
ABI3 0.685 0.567 0.908 
NCR2 0.776 0.664 0.975 
UNC5C 0.797 0.517 0.765 
PTK2B 0.688 0.979 0.899 
MEF2C 0.812 0.695 0.986 
ABCA7 0.082 0.338 0.095 
LMX1B 0.003 0.078 0.276 
TREM2 0.793 0.820 0.963 
ECHDC3 0.805 0.703 0.670 
BIN1 0.663 0.798 0.724 
PSEN2 0.242 0.256 0.356 
CD33 0.876 0.832 0.950 
ZNF804B 0.073 0.141 0.162 
PICALM 0.912 0.922 0.989 
HLA-DRB5 0.973 0.910 0.986 
PSEN1 0.879 0.924 0.866 
INPP5D 0.937 0.987 0.982 
TPBG 0.220 0.240 0.249 
PLCG2 0.943 0.963 0.945 
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The MRC of the RAD genes was appreciably higher for the late stage network 
(0.733) than early stage network (0.615), but the RCs for many individual genes 
including APOE, APP, and MAPT were similar across these two networks (Table 
3.2). Comparison of correlation networks in the cerebrum constructed for each 
individual showed that RAD genes tend to have low variability in RC among 
individuals within this dataset (Figure 3.3). The patterns of co-expression across 
the individual brains is moderately high and consistent with RC values between 
0.455 and 0.652 (Figure 3.4).  
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Table 3.2: RC of RAD Genes in Late and Early Stage Correlation Networks. 
To determine if there was an observable relationship between known AD 
pathology and the high MRC of the RAD genes, we next divided the cerebrum 
network into two parts: one part containing all of the early stage AD regions 
(Braak = 1), and the other part containing the later stage AD regions (Braak = 3). 
For both late and early stage, a network was constructed across the relevant 
brain regions and the MRC of the RAD genes was computed. The late state 
network had higher MRC (0.733) in comparison to the early stage network 
(0.615). 
  
Percentile Ranking by 
Correlation 
Gene Early Late 
UNC5C 0.127 0.997 
TP53INP1 0.093 0.931 
ZCWPW1 0.156 0.979 
ABCG1 0.192 0.956 
PLD4 0.233 0.963 
KCNMB2 0.954 0.269 
ABCA7 0.831 0.180 
CLU 0.822 0.235 
TPBG 0.735 0.163 
CASS4 0.202 0.774 
SLC10A2 0.284 0.851 
ECHDC3 0.951 0.396 
INPP5D 0.363 0.874 
AKAP9 0.647 0.195 
SORL1 0.975 0.529 
SORCS1 0.865 0.419 
LMX1B 0.588 0.158 
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CASP8 0.425 0.851 
OSTN 0.080 0.505 
NCR2 0.492 0.888 
SORCS3 0.482 0.864 
PICALM 0.640 1.000 
C1QTNF4 0.105 0.428 
TRIP4 0.619 0.896 
PSEN1 0.712 0.984 
PSEN2 0.594 0.380 
PILRA 0.489 0.289 
ABI3 0.671 0.867 
PLCG2 0.984 0.794 
ACE 0.065 0.249 
APOE 0.987 0.807 
PTK2B 0.756 0.579 
PDGFRL 0.111 0.272 
SORCS2 0.481 0.641 
MS4A6A 0.728 0.884 
MS4A4A 0.881 0.727 
TREM2 0.849 0.999 
GALNT7 0.737 0.882 
EPHA1 0.330 0.467 
CD2AP 0.531 0.667 
HLA-DRB5 0.847 0.948 
COBL 0.830 0.740 
PLXNA4 0.847 0.760 
CR1 0.610 0.691 
PLD3 0.584 0.647 
MEF2C 0.800 0.739 
PFDN1 0.596 0.657 
ZNF804B 0.219 0.168 
APP 0.676 0.705 
BIN1 0.949 0.925 
CD33 0.977 0.988 
MAPT 0.534 0.526 
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Figure 3.3: The RAD Gene Set Has Consistently High MRC in Each 
Individual. Due to the small number of individuals in the dataset (six), a 
correlation network of the cerebrum was constructed for each of the six brains. 
The MRC for each RAD gene was computed in each of the six individual 
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correlation networks. Depicted here are the MRC for each RAD gene averaged 
across the six individuals. The points denote the mean MRC, and the bars 
denote the 95% confidence intervals. 
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Figure 3.4: Rankings Using RAD Genes Are Consistent in Each Individual 
Brain. In order to test if the network gene scores produced from the RAD genes 
were robust, we computed all genes scores from the RAD genes in each of the 
six individual networks. We then computed the Kendall Tau rank correlation, 
ordering the genes by their scores, for each pairing of individuals. Gene score 
orderings are strongly correlated between all possible pairings of individuals. 
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In order to predict novel AD genes based upon the above observations, a 
network score was produced for each non-RAD gene using the cerebrum 
correlation network in which clustering of the RAD genes was strongest. These 
network scores were then combined with GWAS Z-scores resulting in re-ordered 
AD gene rankings. A normal approximation was used to evaluate the significance 
of the combined scores. These results were filtered using gene knockout 
information from Flybase to limit the focus to genes which have functional 
evidence for producing AD-related phenotypes. Of the remaining 654 genes after 
the final filtering step, there was significant evidence for two novel AD-related 
genes including EPS8 (FDR q-value = 8.77x10-3) and HSPA2 (FDR q-value = 
0.245) (Table 3.3). Several previously reported AD genes also had high rankings 
but were not significant after FDR correction including ADAM10 (FDR q-value = 
0.401) and HDAC1 (FDR q-value = 0.791). Another potential novel candidate 
gene, although not as statistically supported, is CAT (FDR q-value = 0.791) due 
to it influencing three total AD-related phenotypes in flies, which we did not 
observe of any other high ranking genes. 
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Table 3.3. Combined Z-Scores Reveal Novel AD Gene Candidates. Each 
non-RAD gene was assigned a new Z-score based upon an equal weight 
combination of its network and GWAS Z-scores. To further enhance our 
confidence in network gene scores, we then integrated information to include 
only scores for genes that are reported as inducing AD-related phenotypes 
(defective memory = MD, defective aging = DA, oxidative stress = OS, premature 
aging = PA, Alzheimer disease = AD) in flies. In total, 654 genes had phenotypic 
evidence in flies. Here we show all genes which had an unadjusted p-value of < 
0.05. 
 
  
One-Tailed Z-Score P-value 
Gene Name Phenotype GWAS Network Combined Unadjusted FDR 
EPS8 DM 3.16 2.78 4.20 1.34E-05 8.77E-03 
HSPA2 DA 2.98 1.51 3.17 7.51E-04 2.45E-01 
ADAM10 AD 2.61 1.50 2.90 1.84E-03 4.01E-01 
HSPA6 DA 2.13 1.63 2.66 3.88E-03 6.34E-01 
CAMK2A DM 0.94 2.60 2.50 6.13E-03 7.91E-01 
HDAC1 AD,OS 1.40 1.97 2.38 8.55E-03 7.91E-01 
MAPK10 AD,OS 1.58 1.68 2.30 1.06E-02 7.91E-01 
CAT AD,OS 2.31 0.89 2.27 1.17E-02 7.91E-01 
FXR1 DM 0.58 2.60 2.24 1.24E-02 7.91E-01 
CD164 DM 0.90 2.23 2.21 1.34E-02 7.91E-01 
HSPB1 OS 1.58 1.52 2.19 1.43E-02 7.91E-01 
FBXW7 OS 0.66 2.34 2.12 1.69E-02 7.91E-01 
DAGLB OS 1.52 1.48 2.12 1.71E-02 7.91E-01 
NFE2L3 OS 1.71 1.20 2.06 1.98E-02 7.91E-01 
MAFB OS 1.56 1.31 2.03 2.11E-02 7.91E-01 
ITGAX DM 1.67 1.20 2.03 2.11E-02 7.91E-01 
SETBP1 AD 1.26 1.60 2.02 2.14E-02 7.91E-01 
ACHE DM 2.12 0.71 2.00 2.28E-02 7.91E-01 
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ITGAM DM 1.56 1.19 1.94 2.59E-02 7.91E-01 
ITPR1 AD 1.01 1.72 1.93 2.68E-02 7.91E-01 
HBB OS 2.68 0.02 1.91 2.81E-02 7.91E-01 
PLK3 AD 2.16 0.50 1.88 2.98E-02 7.91E-01 
TRIB3 DM 1.35 1.29 1.87 3.08E-02 7.91E-01 
RCAN1 AD,DM,OS 1.24 1.40 1.87 3.10E-02 7.91E-01 
GABARAP DM 0.74 1.87 1.85 3.23E-02 7.91E-01 
NIPBL DM 0.72 1.90 1.85 3.24E-02 7.91E-01 
GPD1 OS 1.54 1.06 1.84 3.26E-02 7.91E-01 
GRIN2A DM 0.98 1.59 1.82 3.47E-02 8.10E-01 
ITPKA OS 0.57 1.95 1.78 3.78E-02 8.29E-01 
DNM1 DM 1.02 1.46 1.76 3.94E-02 8.29E-01 
PGC AD 1.28 1.19 1.75 4.00E-02 8.29E-01 
CIDEC DM 1.60 0.87 1.74 4.06E-02 8.29E-01 
TXNRD2 DA 1.85 0.59 1.73 4.21E-02 8.34E-01 
BZW2 DM 1.60 0.80 1.69 4.51E-02 8.67E-01 
CBX3 AD 1.54 0.81 1.66 4.81E-02 8.91E-01 
PCNA OS 2.31 0.03 1.65 4.91E-02 8.91E-01 
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Discussion 
 
Previous studies using correlation or other network strategies have increased 
discovery and understanding the functional roles of novel disease related genes 
across many biological contexts [19, 26, 27, 124]. In this study, we applied an 
integrative network strategy to capture complex relationships between RAD 
genes across relevant regions of the brain and to aid discovery novel AD-related 
genes. This approach entailed integration of AD GWAS data, gene expression 
measures in multiple brain regions, and phenotypic information (i.e., memory and 
aging-related outcomes) from gene knockout studies in Drosophila [123]. By 
separating regions of the brain according to established patterns of AD-related 
pathology including neurodegeneration and protein aggregation, we showed that 
the correlation of expression between previously established AD genes is highest 
in regions severely impacted by AD, noting gene expression data were derived 
from brains without AD pathology. In addition, we identified potential novel AD 
genes by numerically combining results from analysis of co-expression of 
established AD genes and other genes in relevant brain regions with summary 
statistics from a large AD GWAS.  
 
The most robust novel gene identified by our approach is EPS8. This gene 
encodes epidermal growth factor receptor substrate 8 which is involved in actin 
cytoskeleton regulation and is abundantly expressed in many brain regions [125]. 
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The accumulation of filamentous actin (F-actin) is associated with tau-induced 
neurodegeneration in Drosophila and mouse tauopathy models [126]. Deletion of 
Eps8 in mice leads to a reduction in hippocampal synaptic plasticity and impaired 
cognitive performance [127]. Three genes encoding heat shock proteins (HSPA2, 
HSPA6, and HSPB1) also emerged among our top findings. Notably, HSPA2 
was also identified as related to AD in a recent network analysis in an 
independent dataset [128]. Heat shock proteins have a major role in handling 
misfolded proteins including amyloid-β. [129] Although expression of heat shock 
protein genes has been well studied in AD, [130] there is little evidence for 
association of AD risk with polymorphisms in any members of this gene family 
with AD risk [131].  
 
Several other top-ranked genes in our study have directly or indirectly been 
linked to AD. ADAM10 encodes disintegrin and metalloproteinase 10 which is a 
synaptic enzyme that has been previously shown to limit amyloid-β1-42 peptide 
formation in AD. A variant in ADAM10 recently achieved genome-wide 
significance in one of the largest genetic studies of AD containing more than 
95,000 individuals [132, 133]. The catalase protein encoded by CAT binds with 
amyloid and inhibition of this interaction has been reported to protect cells from 
toxic protein aggregation [134, 135]. Several genes in the HDAC family have 
been reported to impair memory in animal models, and inhibitors of several 
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members of the HDAC gene family, including HDCA1 identified for the first time 
in our study as an AD candidate gene, have been gaining support as a 
therapeutic approach for treating AD [136-139]. In humans, loss of HDAC5 
impairs memory function and variants in HDAC9 have been associated with a 
dual outcome of neurofibrillary tangles and amyloid angiopathy [138, 140]. We 
also obtained mild evidence supporting a role for the gene encoding 
acetylcholinesterase (ACHE). This is a noteworthy finding in light of inconsistent 
and generally negative reports of association for AD with ACHE and related 
genes encoding choline acetyltransferase (CHAT) and butyrylcholinesterase 
(BCHE), despite the fact that AD is characterized by an extensive loss of 
cholinergic neurons from the basal forebrain area and the wide use of 
cholinesterase inhibitors to treat the early stages of cognitive decline [141]. 
 
A major motivation for our approach was to determine if the regional-specific 
effects that AD exhibits biologically can be detected using a correlation network 
approach. Recent work indicates that cell type compositions of brain regions are 
highly variable in aging brains, so cross-regional analysis is able to capture 
important properties such as changing cell fractions that may explain why the 
biological symptoms of AD are not uniformly present throughout the brain [114]. 
The high MRC of the RAD genes in the cerebrum supports this notion, given that 
the cerebrum tends to be the most major structure in the brain affected by AD 
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[105]. Further evidence for this is also provided by the low MRC of the RAD 
genes in the other brain regions (brain stem, cerebellum) where the effect of AD 
is far less severe. Notably, these patterns appear to be consistent in our study of 
cognitively healthy individuals (Figure 3.3). 
 
Our findings also highlight several interesting patterns among several well 
established RAD genes. Expression of APOE and MAPT is highly correlated with 
other RAD genes in the cerebrum to the other RAD genes, but much less in the 
cerebellum and brain stem which is consistent with our previous observation of 
the RAD gene set as a whole. However, expression of APP and other RAD 
genes is highly correlated in the cerebellum (0.99), but not in the cerebrum 
(0.38). One explanation for this peculiar observation is that the hypothesis of 
RAD genes clustering via a correlation metric relies on coordinated changes in 
expression between RAD genes across regions of the brain. APP has consistent 
expression across most regions of the cerebrum, as evidenced in the Gene 
Tissue Expression (GTEx) portal, and thus would not appear correlated with 
genes which have more variable expression in the same regions, such as the 
other RAD genes [142]. A clearer understanding of this pattern will require 
focused analysis of gene co-expression within specific regions in the cerebrum. 
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Interpretation of our results has several caveats. First, we analyzed a dataset 
that has few individuals but a high number of brain regions in which expression 
was measured. However, expression patterns were consistent across individual 
brains in the dataset. If we had chosen instead a publicly available dataset 
containing a larger number of individuals but expression measurements in fewer 
regions, we would not have observed the high variation in expression of the RAD 
genes across regions of the cerebrum. This underscores the need for larger 
samples of brains with expression data in more precisely defined regions. 
Second, the present study did not include any brains from AD individuals. 
Although we utilized known Braak staging to characterize regions, it could be 
meaningful to have measurements of gene expression from these regions at 
varying stages of AD progression in order to understand how the presence of AD 
influences the observations we have noted of the RAD genes. Finally, we did not 
uncover a high number of genes that remained significant after an FDR-
correction. In part, this was due to a power issue as the both the expression and 
genetic datasets used could greatly benefit from the inclusion of additional 
individuals.  
 
This work establishes a strong foundation for many potential follow-up 
investigations. As larger fine-grained brain region expression datasets become 
available it will be important to confirm that the patterns we observed understand 
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how these patterns differ among brains with various stages of AD-related 
pathology. Although highly granular regional expression data from AD brains is 
not readily available, efforts are in progress by the AMP-AD consortium to profile 
expression of various regions of AD brains [143]. Validated differences in cross-
regional correlation patterns between healthy and AD brains would improve 
understanding of mechanisms underlying the progression of AD and inform 
strategies for developing more effective therapeutic targets.  
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Chapter 4: Analysis of Median Ranking by Diffusion of General Phenotype 
Sets and the Effects of Cell Type and Disease on the Clustering Properties 
of Alzheimer Genes  
The multi-omic network approaches employed in earlier chapters have had a 
demonstrable role in clarifying the joint behaviors of the known AD genes as well 
as suggesting several novel candidate AD genes. Associations with several of 
the proposed candidate AD genes have been identified with genome-wide 
statistical evidence in recent studies with vastly larger sample sizes. This 
suggests that the application of network methodology can aid in the robust 
identification of disease-related genes in genetic datasets that would otherwise 
be limited by statistical power. Although genetic studies of diseases such as AD, 
Type 2 diabetes, and several cancers have analyzed sample sizes up to several 
hundred thousand, there remain a wide array of diseases and phenotypes for 
which the identification of candidate genes by GWAS has been hampered by 
sample size. Therefore, the extension of our methodology to these phenotypes 
with more limited samples could vastly aid in expanding their genetic 
understanding. 
In order to improve our understanding of the general effectiveness of the MRD 
approach, we extended the application of our methodology to the abundant 
number of phenotype gene sets available in Flybase [144]. Although Flybase 
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does not contain the genetic data required to test the integration aspect of our 
strategy, the wide variety of phenotype sets certainly allows for testing the 
network approaches that were applied in previous chapters in the context of AD. 
 
An additional motivation of this research was to further the understanding of the 
biological basis for progression of AD-related pathology in the brain. In chapter 3, 
we determined that the co-expression of the RAD genes appears to be related to 
the known pattern of regional progression of AD within the human brain. A logical 
next step is to identify biological differences between brain regions that could 
explain this behavior. Recently, several studies reported measurable differences 
in cell type compositions between regions of the adult human brain [114]. 
Additionally, there is increasing support that microglial and immune cells serve a 
central role in AD progression [145]. Collectively this supports the idea that a cell 
type-related factor may contribute to the differences in expression of the RAD 
genes observed in chapter 3. Finally, in order to understand how relevant factors 
such as aging and the presence of AD can influence the conclusions from 
analyses of healthy brains (see chapter 3), here we extend our methodology to a 
dataset with a wider variety of clinical information for each subject. 
Methods 
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Acquisition and Mapping of Flybase Phenotype Sets to the Human Protein-
Protein Interaction Network 
The Flybase phenotype database was accessed to acquire new gene sets for 
additional testing of the MRD approach [144]. In order to ensure compatibility 
with the existing networks established in prior chapters, the fly genes associated 
with phenotypes needed to be matched to their closest human gene orthologs. 
This matching was accomplished using the DRSC Integrative Ortholog Prediction 
Tool (DIOPT) [146]. Briefly, the DIOPT is a consensus strategy that utilizes the 
high number of ortholog prediction approaches. Each mapping algorithm was 
applied to each fly gene and the human gene ortholog that was predicted most 
commonly across all approaches was selected and was assigned a score based 
upon the number of algorithms that agreed with the mapping. Orthologs with a 
DIOPT score of >3 were deemed high quality [146]. After applying the DIOPT 
approach to the genes in the Flybase phenotype set, 6,300 phenotypes were 
matched with a minimum of two human gene orthologs. 
 
Computing the Median Ranking by Diffusion of Flybase Phenotypes 
The human-mapped Flybase phenotypes were filtered to ensure phenotypes 
being tested had adequate representation in the human PPI network that was 
assembled and described in Chapter 2. All phenotypes that had a minimum of 
five genes in the human PPI network were retained for further analysis. A total of 
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3100 phenotypes remained after this filtering step. Next, the MRD of each 
phenotype was computed within the human PPI network, using the methodology 
described in Chapter 2. Briefly, MRD is a leave one out style approach that 
determines the overall proximity of a set of genes within a network normalized to 
account for the distribution of scores for all genes. The frequencies of different 
ranges of MRD were illustrated in a histogram and several phenotypes were 
highlighted to represent either essential (cell lethality and DNA repair 
defectiveness) or AD-associated phenotypes (oxidative stress and premature or 
defective aging). 
 
Cell Type Deconvolution in Late and Early Stage Regions of AD 
Cell type deconvolution as implemented in the CellMix R package [147] was 
applied to the ABA gene expression data, described in chapter 3, in each region 
using gene markers for microglia (TLR2, CX3CR1, IL1A), neurons (STMN2, 
SYN1, SYT1, GAD1, CCK), and astrocytes (GFAP, ALDH1L1, AQP4, GJA1, 
SOX9) [148-151] in order to obtain frequencies for each cell type in each brain 
sub-region. The regions were then partitioned into two groups corresponding to 
early and late stage AD regions as described in chapter 3. Regions were sorted 
by computing the Shannon entropy among cell types in each region [152]. Briefly, 
entropy is a measure of the variability of a region. Regions with an equal mixture 
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of many cell types would therefore have high entropy, and regions that are 
dominated by mostly one cell type have low entropy. 
 
Determining Changes in MRC of RAD Genes in Brains Due to Aging and AD 
In order to determine the possible effects AD and other AD-related risk factors 
(such as age) on the MRC of the RAD genes, the approach described above was 
applied to an independent dataset from the Mount Sinai Brain Bank (MSBB). The 
MSBB dataset contains gene expression measurements for as many as 21 sub-
regions of the brain per individual and is comprised of approximately 40 AD 
cases and 40 controls. The MSBB dataset was accessed via the publicly 
available AMP-AD web portal on Synapse (synapse.org). Individuals who had 
measurements in five or fewer regions or were > 90 years of age were excluded 
since all ages above 90 are reported as 90 to maintain anonymity of subjects, 
and mislabeled ages would sharply interfere with fitting a linear model. A total of 
32 individuals remained after applying these filtering criteria. For each remaining 
individual, the absolute correlation was computed for all possible gene pairs 
across available brain regions. Then the MRC of the RAD genes was determined 
for each of these individual correlation networks. Finally, the resulting MRCs 
were regressed against the age and AD status of the individuals. 
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Results 
 
Flybase Phenotypes Have High MRDs in Human PPI Network 
After applying the MRD approach for each qualifying Flybase phenotype, the 
majority of the gene sets had many inner-set connections between gene 
members. Nearly perfect (> 0.98) MRDs were observed for small gene sets (n < 
10), and this result was not surprising since the genes in these small sets often 
form densely connected neighborhoods or linear chains in the human PPI 
network. Most of the remaining gene sets had MRDs between 0.85 and 0.90. 
The MRDs for the AD-related phenotypes (Figure 4.1) were calculated as 0.75 
(oxidative stress), 0.82 (premature aging), 0.83 (defective aging), and 0.9 
(defective DNA repair) which is lower than the average of Flybase phenotypes in 
general (Figure 4.2). 
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Figure 4.1: Overview of MRDs of Important AD and Survival Phenotypes. 
The MRDs of the AD-related phenotypes used in chapter 3 (Oxidative Stress, 
Premature Again, and Aging Defective) as well as two representative survival 
phenotypes (Cell Lethality, DNA Repair) were examined. The MRDs of the 
selected sets (highlighted in red) were above a random set, but notably at or 
below average of the Flybase sets as a whole with the exception of DNA repair.  
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Figure 4.2: Flybase phenotype sets have high MRD in human PPI network. 
6,297 phenotype gene sets were mapped to the human PPI network. The above 
histogram depicts the frequency of MRD values across these sets. Most of the 
phenotype sets from Flybase tended to have MRD above the random model of 
0.5, with a high number being small sets of very closely clustered genes resulting 
in a large number of sets having MRDs that were in the 0.98 to 1 range. 
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Cell Types Compositions are Notably Different between Late and Early Stage 
Regions 
Deconvolution was applied to the ABA data in order to identify potential cell type 
differences between the various regional co-expression networks. Overall the 
early stage regions tended to be composed predominantly of neurons, with a 
much smaller fraction of microglia and astrocytes (Figure 4.3). By contrast, the 
late regions displayed a more balanced representation of these three cell types 
(Figure 4.4).  
  
79 
 
 
 
Figure 4.3: Cell Type Compositions of the Early Stage Regions: The cell type 
composition of 96 early stage regions was determined using deconvolution. Each 
column corresponds to a single region, and the sum of the three cell types for 
each region sum to one. Neurons (blue) were the dominant cell type in the vast 
majority of the early stage regions. Microglia (green) and Astrocytes (red) were 
slightly represented in most regions. 
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Figure 4.4: Cell Type Compositions of the Late Stage Regions. The cell type 
compositions of 37 early stage regions were determined using deconvolution. 
Each column corresponds to a single region, and the sum of the three cell types 
for each region sum to one. While neurons (blue) tended to be the most 
common, there are also a notable number of regions in which microglia (green) 
or astrocytes (red) were the dominant cell type. Overall the late stage regions 
display much higher variability in cell type in comparison to the early stage 
regions (Figure 4.3). 
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RAD Genes Have High MRC in Healthy and Young Individuals 
The MRD of the RAD genes was determined in each individual, and regressed 
against their age and AD status. At high ages, there does not appear to be a 
meaningful distinction between AD cases and control (See Figure 4.5). However, 
at younger ages, there appears to be a much larger separation. Due to limited 
sample size, it cannot be determined if this trend is robust, given that the 95% 
confidence intervals (dark gray in Figure 4.5) for the slopes of the regression 
lines clearly overlap. 
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Figure 4.5: The Effects of Age and AD on the MRC of the RAD Genes. The 
MRC was computed within each individual in the MSBB dataset. AD cases (red) 
tended to have a much lower MRC for the RAD genes than age equivalent 
controls (blue). At higher ages, the MRC of the RAD genes tended to be 
indistinguishable in either group. 
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Discussion 
 
In the earlier chapters, methodology for identifying novel disease-associations to 
genes was applied to an AD disease set. Ideally, this approach should be applied 
to curated datasets for other diseases in order to generalize its utility. However, 
publicly available data for many other diseases are either outdated or compiled 
using less stringent criteria for establishing genes as associated with disease. 
The assembly of a RAD gene set carried out using a manual assembly approach 
(see Chapter 2) required literature curation of several decades of research and 
thus may not be practical for some diseases. A more efficient strategy would be 
to apply our methodology to phenotype sets that can be assembled more 
efficiently using high throughput knockout screening in a suitable model organism 
such as Drosophila or c. elegans. 
There are several explanations for our observation of a very high MRD of 
Flybase phenotypes on average (Figure 4.1). First, phenotypes in Flybase 
correspond to very specific human traits that can be screened in flies and, thus, 
may be more closely related than disease sets such as the RAD set (described in 
chapter 2) which may contain genes fulfilling a wider variety of biological roles. 
Whereas RAD genes may span a larger portion of the PPI network, Flybase 
phenotypes are likely localized to very specific areas of the interaction network. 
Second, there is a tautology between model organism screening and the addition 
of interactions to human PPI networks, i.e. when a small set of genes are shown 
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to be functionally related in animal models, the human orthologs of these genes 
will be tested subsequently and more likely be added to PPI databases than 
other genes.  
It is surprising that a phenotype as detrimental as cell lethality had a lower MRD 
than an average Flybase phenotype (Figure 4.2). This may be due in part to the 
size of gene sets which can vary widely based upon the number and complexity 
of biological pathways related to the trait. In addition, some extreme phenotypes 
such as lethality are less specific because they can be induced by the shutdown 
of many essential processes and are therefore not localized to any particular 
pathway.  
Genes with cell type specific expression can serve as markers that form the 
basis for several deconvolution approaches which approximate cell type fractions 
based upon the relative expression of these genes. Marker-based strategies 
have the advantage of being applicable in silico to any expression dataset 
without requiring the original biological samples for lab-based testing, which 
enabled us to determine the cell types underlying the ABA data. Single cell 
sequencing technologies have identified numerous markers that can be used for 
a wide variety of phenotypes. 
The results we observe after deconvolution suggest that the underlying cell types 
of the brain regions could be responsible for the changes in clustering of the RAD 
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genes that was previously observed in chapter 3. The early stage regions, where 
the MRC of the RAD genes was slightly lower, are dominantly composed of 
neuronal cell types (Figure 4.3). The later stage regions, where the MRC of the 
RAD genes was higher, are a balanced mixture of the three tested cell types 
(Figure 4.4). This would suggest that the RAD genes tend to have stronger co-
expression to one another in microglia and astrocytes than in neurons. It is also 
worth noting that cell type seems to be a fairly good indicator of either early or 
late stage regions. The regions of the brain that are most susceptible to AD in its 
early phases tend to be predominantly composed of neurons. The regions which 
are not affected until much later in AD progression, have a much smaller of 
fraction of neurons. Given that AD is by definition a neurodegenerative disease, 
this would seem consistent with what is known biologically. There may also be 
protective effects resulting from the higher levels of astrocytes and microglial 
cells that insulate these regions from AD-related damage early on in the disease 
progression. 
We observed that a reasonable separation occurs in MRD between young AD 
cases and controls (Figure 4.5). As individuals age however, this separation 
diminishes (Figure 4.5). This could be for a variety of reasons. Age is the most 
critical risk factor for AD, given that AD cases tend to not begin until around age 
65 (except for rare familial early onset cases), after which point the prevalence 
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rate of AD increases rapidly to nearly 40% by age 80 [153]. Therefore, healthy 
older individuals still share aging-related biological changes with the older AD 
individuals that might mask and overwhelm any disease related differences. 
It is notable that young and healthy individuals tended to have the highest MRCs 
of the RAD genes in the MSBB (Figure 4.5) and the ABA (chapter 3) datasets. 
Another key observation is that the MRC was greater in brain sub-regions which 
are spared early in the disease. Both of these observations are in agreement that 
co-expression of RAD genes is strongest in regions or individuals that are 
resilient to developing AD. RAD genes may simply be poorly co-expressed in AD 
individuals as a consequence of the underlying damage to the brain specimens. 
However, it would be highly informative if it was determined that the direction of 
causation is the opposite in that a breakdown in RAD gene co-expression 
elevates AD risk. If the direction of causation in this relationship can be 
determined in future studies, it could greatly improve our understanding of the 
therapeutic benefits of influencing RAD gene expression. 
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Chapter 5: Conclusions and Future Projects 
The work presented in the chapters of this thesis provide further support for the 
benefit of multi-omic integration in the study of phenotypes and disease. Often 
times the difficulty of appropriately incorporating additional data types into an 
analysis discourages doing so. However, in this work we have demonstrated a 
very intuitive and simple to implement framework for re-prioritizing analysis 
results from existing statistical approaches that does not require any substantial 
changes to the existing methodology. The specific emphasis of this work has 
been on re-prioritization of genes from GWAS, however the framework can just 
as easily be applied to any other form of gene-level statistics relating to disease, 
such as differential expression analysis, expression Quantitative Trait Loci 
(eQTL) amongst many others. Several of the top genes proposed by the various 
applications of our integration approach have been replicated in very recent 
studies involving substantially larger sample sizes which demonstrates the 
robustness multi-omic analyses can achieve. Reaching massive sample sizes in 
sequencing studies is a costly and time-consuming endeavor, and so it stands to 
reason that making the best use of all presently available resources is an efficient 
exercise in the interim. 
There are several clear opportunities for further development of this methodology 
that have not yet been fully explored. One such option is to determine the 
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potential benefits of simultaneously utilizing both the PPI and regional co-
expression networks within a single analysis (See Figure 5.1). Biologically, it is 
not necessarily the case that two genes which interact necessarily need to be co-
expressed. For example, genes in the blue region would correspond to such 
genes which interact but are not expressed in the brain, but rather are active in 
alternative tissues. By contrast, purple would be genes which are co-expressed 
in the brain, but do not have known protein interactions potentially because they 
have not been tested in proper environmental conditions. 
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Figure 5.1: Overview of Possible Combinations of Protein Interactions and 
Co-Expression. Two different types of networks were constructed in this work. 
First, a protein interaction network (X-axis) and second, co-expression networks 
in the brain (Y-axis). It is not necessarily the case that genes would receive 
similar scores in both of these networks, as highlighted here. 
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Genes which are similarly ranked in both networks are arguably the most simple 
to interpret, however this should not lead to overlooking the potential information 
that gain be obtained from following up on the cases of rankings which are 
discrepant between the PPI and coexpression networks. The development of 
tissue specific protein interactions network has been a growing area of research 
that seeks to clarify this issue, such as the recently developed TissueNet 
database [154]. Many protein-protein interactions are known to be heavily 
influenced by the environment in which they occur [154]. Therefore, the general 
PPI network (chapter 2) could contain interactions which do not occur in the 
essential areas of the brain where AD pathology is most active (chapter 3). The 
usage of tissue specific PPI data to further refine general networks to be more 
appropriate for a particular disease is therefore one potential improvement upon 
our existing methodology. However, there will still likely be genes that have 
discrepant rankings between a tissue/region specific PPI and a coexpression 
network of the relevant tissue. Many steps are involved in the activation of a 
biological pathway, usually beginning with a change in the cellular environment 
that activates a signaling cascade. The chain of interactions that occurs as part 
of a signaling cascade tend to resemble a ripple effect. So whereas a PPI 
network will generally represent all interactions underlying a pathway that would 
occur over time as the pathway is activating, a regional coexpression network 
reflects a static snapshot of the expression landscape at a given point in time. 
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Therefore this should be kept in mind during the design of any approach that 
attempts to harmonize all the earlier chapters of this work. 
Another potential improvement to the methodology is related to how the seeded 
disease genes (the RAD genes, for example) are represented. Initially, we have 
treated all genes in the RAD set as having an equally important role in AD. 
Genetically, this is known to be false given that APOE explains more of the 
heritability of late onset AD than any of the other known RAD genes [6]. It could 
therefore be optimal to weight the individual RAD genes based upon some metric 
of their statistical significance to AD. However, there are a tremendous number of 
factors that need to be accounted for when doing this such as sample size, 
appropriate correction for confounding variable, ethnic-specific effects, amongst 
many others. The choice to leave the RAD genes unweighted allowed us to focus 
on gauging the general effectiveness of the approach, but exploring different 
options for the initialization of the method would certainly be ideal in the future. 
Finally, there are many different pathways that underlie diseases as biologically 
complex as AD. Therefore, it may make sense to divide the RAD gene set into 
subsets that reflect specific known biology. This however can be difficult, given 
that overall there are a high number of proposed AD-related pathways, and it 
isn’t fully clear how each individual RAD gene corresponds to them. Clustering 
can be done to determine subsets of the RAD genes automatically, but this can 
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be heavily influenced by the choice of algorithm and parameters. In our initial 
exploration of simple clustering approaches, we found that each sub-cluster did 
appear enriched for specific AD-related processes, such as aging, inflammation, 
and neurodegeneration. This style of approach could therefore allow for a more 
pathway-driven investigation into disease than we are considering presently. 
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